Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) EBITDA: 2015-2025

Historic EBITDA for Cartesian Therapeutics (RNAC) over the last 11 years, with Sep 2025 value amounting to -$35.9 million.

  • Cartesian Therapeutics' EBITDA fell 48.41% to -$35.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.0 million, marking a year-over-year increase of 80.41%. This contributed to the annual value of -$77.4 million for FY2024, which is 64.76% up from last year.
  • As of Q3 2025, Cartesian Therapeutics' EBITDA stood at -$35.9 million, which was down 325.89% from $15.9 million recorded in Q2 2025.
  • Cartesian Therapeutics' 5-year EBITDA high stood at $28.7 million for Q1 2022, and its period low was -$177.6 million during Q4 2023.
  • Moreover, its 3-year median value for EBITDA was -$17.7 million (2025), whereas its average is -$30.4 million.
  • Per our database at Business Quant, Cartesian Therapeutics' EBITDA crashed by 3,128.85% in 2023 and then skyrocketed by 221.34% in 2024.
  • Over the past 5 years, Cartesian Therapeutics' EBITDA (Quarterly) stood at $12.2 million in 2021, then plummeted by 52.05% to $5.9 million in 2022, then plummeted by 3,128.85% to -$177.6 million in 2023, then soared by 94.22% to -$10.3 million in 2024, then plummeted by 48.41% to -$35.9 million in 2025.
  • Its EBITDA was -$35.9 million in Q3 2025, compared to $15.9 million in Q2 2025 and -$17.7 million in Q1 2025.